AIMS: Community-based pharmacists are an important stakeholder in providing continuing care for chronic multi-morbid patients, and their role is steadily expanding. The aim of this study is to examine the literature exploring community-based pharmacist-initiated and/or -led deprescribing and to evaluate the impact on the success of deprescribing and clinical outcomes. METHODS: Library and clinical trials databases were searched from inception to March 2020. Studies were included if they explored deprescribing in adults, by community-based pharmacists and were available in English. Two reviewers extracted data independently using a pre-agreed data extraction template. Meta-analysis was not performed due to heterogeneity of study designs, types of intervention and outcomes. RESULTS: A total of 24 studies were included in the review. Results were grouped based on intervention method into four categories: educational interventions; interventions involving medication review, consultation or therapy management; pre-defined pharmacist-led deprescribing interventions; and pharmacist-led collaborative interventions. All types of interventions resulted in greater discontinuation of medications in comparison to usual care. Educational interventions reported financial benefits as well. Medication review by community-based pharmacist can lead to successful deprescribing of high-risk medication, but do not affect the risk or rate of falls, rate of hospitalisations, mortality or quality of life. Pharmacist-led medication review, in patients with mental illness, resulting in deprescribing improves anticholinergic side effects, memory and quality of life. Pre-defined pharmacist-led deprescribing did not reduce healthcare resource consumptions but can contribute to financial savings. Short follow-up periods prevent evaluation of long-term sustainability of deprescribing interventions. CONCLUSION: This systematic review suggests community-based pharmacists can lead deprescribing interventions and that they are valuable partners in deprescribing collaborations, providing necessary monitoring throughout tapering and post-follow-up to ensure the success of an intervention.

City Pharmacies Zagreb Zagreb Croatia

Department of Social and Clinical Pharmacy Faculty of Pharmacy in Hradec Králové Charles University Prague Czech Republic

Faculty of Pharmacy and Biochemistry University of Zagreb Zagreb Croatia

Zobrazit více v PubMed

Tasaka Y, Yasunaga D, Tanaka M, et al. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan. Int J Clin Pharmacol. 2016;38(2):321-329. https://doi.org/10.1007/s11096-015-0245-6

Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their impact on patients' medication adherence and other health outcomes: a systematic review. Int J Pharm Pract. 2018;26(5):387-397. https://doi.org/10.1111/ijpp.12462

Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of “deprescribing” with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254-1268. https://doi.org/10.1111/bcp.12732

Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583-623. https://doi.org/10.1111/bcp.12975

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The EQUATOR Network. https://www.equator-network.org/reporting-guidelines/prisma/. Accessed September 21, 2020.

Aromataris E, Munn Z. JBI Manual for Evidence Synthesis. JBI; 2020 doi: 10.46658/JBIMES-20-01.

Joanna Briggs Institute. JBI Levels of Evidence Supporting Documents-v2.pdf. https://joannabriggs.org/sites/default/files/2019-05/JBI%20Levels%20of%20Evidence%20Supporting%20Documents-v2.pdf. Accessed September 22, 2020.

Joanna Briggs Institute. Critical Appraisal Tools. https://joannabriggs.org/critical-appraisal-tools. Accessed September 23, 2020.

van der Meer HG, Wouters H, Pont LG, Taxis K. Reducing the anticholinergic and sedative load in older patients on polypharmacy by pharmacist-led medication review: a randomised controlled trial. BMJ Open. 2018;8(7):e019042. https://doi.org/10.1136/bmjopen-2017-019042

Lenander C, Elfsson B, Danielsson B, Midlöv P, Hasselström J. Effects of a pharmacist-led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial. Scand J Prim Health Care. 2014;32(4):180-186. https://doi.org/10.3109/02813432.2014.972062

Campins L, Serra-Prat M, Gózalo I, et al. Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Pract. 2017;34(1):36-42. https://doi.org/10.1093/fampra/cmw073

Sathienluckana T, Unaharassamee W, Suthisisang C, Suanchang O, Suansanae T. Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist-physician collaboration in the outpatient department. Integr Pharm Res Pract. 2018;7:161-171. https://doi.org/10.2147/IPRP.S176653

Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890-898. https://doi.org/10.1001/jamainternmed.2014.949

Navy HJ, Weffald L, Delate T, Patel RJ, Dugan JP. Clinical pharmacist intervention to engage older adults in reducing use of alprazolam. Consult Pharm. 2018;33(12):12.

Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA. 2018;320(18):1889-1898. https://doi.org/10.1001/jama.2018.16131

Mott DA, Martin B, Breslow R, et al. Impact of a medication therapy management intervention targeting medications associated with falling: results of a pilot study. J Am Pharm Assoc. 2016;56(1):22-28. https://doi.org/10.1016/j.japh.2015.11.001

Blalock SJ, Casteel C, Roth MT, Ferreri S, Demby KB, Shankar V. Impact of enhanced pharmacologic care on the prevention of falls: a randomized controlled trial. Am J Geriatr Pharmacother. 2010;8(5):428-440. https://doi.org/10.1016/j.amjopharm.2010.09.002

Cossette B, Taseen R, Roy-Petit J, et al. A pharmacist-physician intervention model using a computerized alert system to reduce high-risk medication use in primary care. Eur J Clin Pharmacol. 2019;75(7):1017-1023. https://doi.org/10.1007/s00228-019-02660-x

Clark CM, LaValley SA, Singh R, Mustafa E, Monte SV, Wahler RG. A pharmacist-led pilot program to facilitate deprescribing in a primary care clinic. J Am Pharm Assoc. 2020;60(1):105-111. https://doi.org/10.1016/j.japh.2019.09.011

Coffey CP, Barnette DJ, Wenzke JT, Lawrence J. Implementing a systematic approach to deprescribing proton pump inhibitor therapy in older adults. Sr Care Pharm. 2019;34(1):47-55. https://doi.org/10.4140/TCP.n.2019.47

Mudge A, Radnedge K, Kasper K, et al. Effects of a pilot multidisciplinary clinic for frequent attending elderly patients on deprescribing. Aust Health Rev. 2016;40(1):86-91. https://doi.org/10.1071/AH14219

Sakakibara M, Igarashi A, Takase Y, Kamei H, Nabeshima T. Effects of prescription drug reduction on quality of life in community-dwelling patients with dementia. J Pharm Pharm Sci. 2015;18(5):705-712. https://doi.org/10.18433/J37P5X

Cross AJ, George J, Woodward MC, Le VJ, Elliott RA. Deprescribing potentially inappropriate medications in memory clinic patients (DePIMM): a feasibility study. Res Social Adm Pharm. 2020;16(10):1392-1397. https://doi.org/10.1016/j.sapharm.2020.01.010

Deyo JC, Smith BH, Biola H, et al. Reducing high-risk medication use through pharmacist-led interventions in an outpatient setting. J Am Pharm Assoc. 2020;60(4):e86-e92. https://doi.org/10.1016/j.japh.2020.01.013

Lupu AM, Clinebell K, Gannon JM, Ellison JC, Chengappa KNR. Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders. J Clin Psychiatry. 2017;78(9):e1270-e1275. https://doi.org/10.4088/JCP.16m11269

Vande Griend JP. Unnecessary lipid-lowering drugs in an outpatient geriatric clinic. Consult Pharm. 2014;29(10):698-702. https://doi.org/10.4140/TCP.n.2014.698

Ammerman CA, Simpkins BA, Warman N, Downs TN. Potentially inappropriate medications in older adults: deprescribing with a clinical pharmacist: CPS impact on inappropriate medication burden. J Am Geriatr Soc. 2019;67(1):115-118. https://doi.org/10.1111/jgs.15623

Hui RL, Chang CC, Niu F, et al. Evaluation of a pharmacist-managed antidiabetic deprescribing program in an integrated health care system. J Manag Care Spec Pharm. 2019;25(8):927-934. https://doi.org/10.18553/jmcp.2019.25.8.927

Stuhec M, Gorenc K, Zelko E. Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation. BMC Health Serv Res. 2019;19(1):118. https://doi.org/10.1186/s12913-019-3942-3

Kouladjian O'Donnell L, Gnjidic D, Chen TF, Hilmer SN. Integration of an electronic Drug Burden Index risk assessment tool into Home Medicines Reviews: deprescribing anticholinergic and sedative medications. Ther Adv Drug Saf. 2019;10:2042098619832471. https://doi.org/10.1177/2042098619832471

Odenthal DR, Philbrick AM, Harris IM. Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic. J Am Pharm Assoc. 2020;60(1):100-104. https://doi.org/10.1016/j.japh.2019.08.012

Sanyal C, Turner JP, Martin P, Tannenbaum C. Cost-effectiveness of pharmacist-led deprescribing of NSAIDs in community-dwelling older adults. J Am Geriatr Soc. 2020;68(5):1090-1097. https://doi.org/10.1111/jgs.16388

Goldstone LW, Saldaña SN, Werremeyer A. Pharmacist provision of patient medication education groups. Am J Health Syst Pharm. 2015;72(6):487-492. https://doi.org/10.2146/ajhp140182

Fajardo MA, Weir KR, Bonner C, Gnjidic D, Jansen J. Availability and readability of patient education materials for deprescribing: an environmental scan. Br J Clin Pharmacol. 2019;85(7):1396-1406. https://doi.org/10.1111/bcp.13912

Turner JP, Currie J, Trimble J, Tannenbaum C. Strategies to promote public engagement around deprescribing. Ther Adv Drug Saf. 2018;9(11):653-665. https://doi.org/10.1177/2042098618794165

Freeman C, Cottrell WN, Kyle G, Williams I, Nissen L. Integrating a pharmacist into the general practice environment: opinions of pharmacist's, general practitioner's, health care consumer's, and practice manager's. BMC Health Serv Res. 2012;12(1):229. https://doi.org/10.1186/1472-6963-12-229

Hazen ACM, de Bont AA, Leendertse AJ, et al. How clinical integration of pharmacists in general practice has impact on medication therapy management: a theory-oriented evaluation. Int J Integr Care. 2019;19(1):1. https://doi.org/10.5334/ijic.3291

Hayhoe B, Cespedes JA, Foley K, Majeed A, Ruzangi J, Greenfield G. Impact of integrating pharmacists into primary care teams on health systems indicators: a systematic review. Br J Gen Pract. 2019;69(687):e665-e674. https://doi.org/10.3399/bjgp19X705461

Freudenberg DL, Covington LP, Young RB, Lopez ND, Patel MV, MacLaughlin EJ. Impact of a pharmacist-driven protocol to improve guideline-concordant prescribing of diabetes medications in patients with atherosclerotic cardiovascular disease: a pilot study. J Pharm Pract. 2020;897190020958245. https://doi.org/10.1177/0897190020958245

Deprescribing Guidelines and Algorithms. Deprescribing.org. https://deprescribing.org/resources/deprescribing-guidelines-algorithms/. Accessed November 18, 2020.

Scott I, Anderson K, Freeman C. Review of structured guides for deprescribing. Eur J Hosp Pharm. 2017;24(1):51-57. https://doi.org/10.1136/ejhpharm-2015-000864

Ruiz-Millo O, Climente-Martí M, Navarro-Sanz JR. Improvement on prescribing appropriateness after implementing an interdisciplinary pharmacotherapy quality programme in a long-term care hospital. Eur J Hosp Pharm Sci Pract. 2018;25(5):267-273. https://doi.org/10.1136/ejhpharm-2017-001411

Ros JJW, Koekkoek TJ, Kalf A, van den Bemt PMLA, Van Kan HJM. Impact of joint consultation by a clinical pharmacist and a clinical geriatrician to improve inappropriate prescribing for elderly patients. Eur J Hosp Pharm Sci Pract. 2017;24(1):26-30. https://doi.org/10.1136/ejhpharm-2016-000916

Rakvaag H, Søreide GE, Meland E, Kjome RL. Complementing or conflicting? How pharmacists and physicians position the community pharmacist. Pharm Pract. 2020;18(3):2078. https://doi.org/10.18549/PharmPract.2020.3.2078

Kelly DV, Bishop L, Young S, Hawboldt J, Phillips L, Keough TM. Pharmacist and physician views on collaborative practice. Can Pharm J. 2013;146(4):218-226. https://doi.org/10.1177/1715163513492642

Chevalier B, Neville HL, Thompson K, Nodwell L, MacNeil M. Health care professionals' opinions and expectations of clinical pharmacy services on a surgical ward. Can J Hosp Pharm. 2016;69(6):439-448.

Eltorki Y, Abdallah O, Omar N, Zolezzi M. Perceptions and expectations of health care providers towards clinical pharmacy services in a mental health hospital in Qatar. Asian J Psychiatr. 2019;42:62-66. https://doi.org/10.1016/j.ajp.2019.03.018

Smith WE, Ray MD, Shannon DM. Physicians' expectations of pharmacists. Am J Health Syst Pharm. 2002;59(1):50-57. https://doi.org/10.1093/ajhp/59.1.50

Alhossan A, Alazba A. Barriers interfering with establishment of Collaborative Drug Therapy Management (CDTM) agreements between clinical pharmacists and physicians. Saudi Pharm J. 2019;27(5):713-716. https://doi.org/10.1016/j.jsps.2019.04.006

Korenvain C, MacKeigan L, Dainty K, Guilcher SJT, McCarthy L. Exploring deprescribing opportunities for community pharmacists: protocol for a qualitative study. Can Pharm J. 2018;151(4):228-232. https://doi.org/10.1177/1715163518778301

Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and enablers of deprescribing: a general practitioner perspective. PLoS ONE. 2016;11(4):e0151066. https://doi.org/10.1371/journal.pone.0151066

Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544. https://doi.org/10.1136/bmjopen-2014-006544

Harriman K, Howard L, McCracken RK. Deprescribing medications for frail elderly patients in nursing homes: a survey of Vancouver family physicians. BC Med J. 2014;56(9):436-441.

Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793-807. https://doi.org/10.1007/s40266-013-0106-8

Dhalwani NN, Fahami R, Sathanapally H, Seidu S, Davies MJ, Khunti K. Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open. 2017;7(10):e016358. https://doi.org/10.1136/bmjopen-2017-016358

Marvin V, Ward E, Poots AJ, Heard K, Rajagopalan A, Jubraj B. Deprescribing medicines in the acute setting to reduce the risk of falls. Eur J Hosp Pharm. 2017;24(1):10-15. https://doi.org/10.1136/ejhpharm-2016-001003

Karani MV, Haddad Y, Lee R. The role of pharmacists in preventing falls among America's older adults. Front Public Health. 2016;4:250. https://doi.org/10.3389/fpubh.2016.00250

Merrill BS, Tak CR, Feehan M, Munger MA. Payers' perspectives on pharmacist-directed care in a community pharmacy setting. Ann Pharmacother. 2019;53(9):916-921. https://doi.org/10.1177/1060028019839440

Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017;6:37-46. https://doi.org/10.2147/IPRP.S108047

Son H, Kim J, Kim C, Ju J, Lee Y, Rhie SJ. Pharmacist-led interdisciplinary medication reconciliation using comprehensive medication review in gynaecological oncology patients: a prospective study. Eur J Hosp Pharm. 2018;25(1):21-25. https://doi.org/10.1136/ejhpharm-2016-000937

Kua C-H, Yeo CYY, Char CWT, et al. Nursing home team-care deprescribing study: a stepped-wedge randomised controlled trial protocol. BMJ Open. 2017;7(5):e015293. https://doi.org/10.1136/bmjopen-2016-015293

Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing medications for chronic diseases management in primary care settings: a systematic review of randomized controlled trials. J Am Med Dir Assoc. 2018;19(11):923-935.e2. https://doi.org/10.1016/j.jamda.2018.06.021

Pruskowski JA, Springer S, Thorpe CT, Klein-Fedyshin M, Handler SM. Does deprescribing improve quality of life? A systematic review of the literature. Drugs Aging. 2019;36(12):1097-1110. https://doi.org/10.1007/s40266-019-00717-1

Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35(4):303-319. https://doi.org/10.1007/s40266-018-0536-4

Barnett ER, Trepman AZ, Fuson HA, et al. Deprescribing psychotropic medications in children: results of a national qualitative study. BMJ Qual Saf. 2020;29(8):655-663. https://doi.org/10.1136/bmjqs-2019-010033

Grudnikoff E, Bellonci C. Deprescribing in child and adolescent psychiatry-a sorely needed intervention. Am J Ther. 2017;24(1):e1-e2. https://doi.org/10.1097/MJT.0000000000000552

Horace AE, Ahmed F. Polypharmacy in pediatric patients and opportunities for pharmacists' involvement. Integr Pharm Res Pract. 2015;4:113-126. https://doi.org/10.2147/IPRP.S64535